New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...
GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...
Colorado's health department is working to get more information out to the public about circulating respiratory viruses. It’s ...
Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...
Clinician-scientists from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and Boston Children’s Hospital analyzed samples from patients’ airways and ...
Hosted on MSN3d
What It’s Like to Have RSV as an Older AdultAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted ... You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a ...
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Pfizer has reportedly ended its Phase II/III trials for sisunatovir, a promising RSV candidate acquired with ReViral in a ...
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...
The Oklahoma State Department of Health is sharing highlights to be proactive during respiratory season as each year ...
COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.
Collaboration will support Controlled Human Infection Model (CHIM) studies to accelerate development of effective and affordable RSV vaccinesNantes, France and Heidelberg, Germany, October 8, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback